Deploying: done (8 seconds) Pruned images: 0 (layers: 0, objsize: 36.9 MB)
Infigratinib靶向的FGFR3（成纤维细胞生长因子受体3）正是驱动ACH疾病发生的关键靶点，2月12日，BridgeBio公布Infigratinib在ACH中取得的首个具有统计学显著改善意义的3期顶线结果，公司计划下半年向FDA提交新药申请。
。业内人士推荐旺商聊官方下载作为进阶阅读
If a line was the same as it was on the last frame, it was skipped
If a line was the same as it was on the last frame, it was skipped